Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372578 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT02372578 is a Phase 2 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 115 participants.
The verdict
NCT02372578, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo. The analgesic effect is evaluated by measuring percent responders, change in daily worst pain score, change in average daily pain score, Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC).
Interventions
- DRUG pregabalin
- DRUG ASP3662
- DRUG ASP3662 placebo
- DRUG pregabalin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2015-05-27 |
| Est. Completion | 2016-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02372578
The ClinicalTrials.gov registry entry for NCT02372578 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pregabalin is the first listed.
NCT02372578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02372578 about?
NCT02372578 is a clinical study titled "Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy". The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo. The analgesic effect is evaluated by measuring percent responders, ch...
What is the current status of trial NCT02372578?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2015-05-27. Estimated completion is 2016-05-20.
What interventions are being tested in trial NCT02372578?
The interventions under investigation include: pregabalin (DRUG), ASP3662 (DRUG), ASP3662 placebo (DRUG), pregabalin placebo (DRUG).
Who is sponsoring clinical trial NCT02372578?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.